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DOI 10.1016/j.ccr.2010.05.027SUMMARYChe-1 is a RNA polymerase II binding protein involved in the regulation of gene transcription and, in response
to DNA damage, promotes p53 transcription. In this study, we investigated whether Che-1 regulates mutant
p53 expression. We found that Che-1 is required for sustaining mutant p53 expression in several cancer cell
lines, and that Che-1 depletion by siRNA induces apoptosis both in vitro and in vivo. Notably, loss of Che-1
activates DNA damage checkpoint response and induces transactivation of p73. Therefore, these findings
underline the important role that Che-1 has in survival of cells expressing mutant p53.INTRODUCTION
Che-1 (also named AATF and Traube) is an evolutionary
conserved RNA polymerase II binding protein involved in the
regulation of gene transcription (Fanciulli et al., 2000; Thomas
et al., 2000; Lindfors et al., 2000; Page et al., 1999; Burgdorf
et al., 2004; Bruno et al., 2002). Che-1 interactswith Rb and inter-
feres with the Rb-mediated recruitment of histone deacetylase I
on the promoters of E2F1-responsive genes, inhibiting the Rb
growth suppressing functions (Fanciulli et al., 2000; Bruno
et al., 2002). In agreement, the mouse Traube is essential for
proliferation in early embryogenesis (Thomas et al., 2000). In
addition to pro-proliferative function, Che-1 exhibits strong anti-
apoptotic activity (Page et al., 1999; Guo and Xie, 2004), and
this protein is downregulated during apoptosis through its inter-Significance
The p53 gene is themost frequent target for genetic alterations
p53 tumor suppressor activity, but gain specific properties con
are often correlated with poor prognosis. Therefore, mutant p
Here, we provide evidence that Che-1 depletion strongly decre
tion, Che-1 depletion induces p73 transcription and apoptosis
findings suggest a therapeutic approach involving the simu
approach could be used to target the large fraction of human
122 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.action with MDM2 (De Nicola et al., 2007) and NRAGE (Di Certo
et al., 2007). Recently, we have shown that in response to DNA
damage, Che-1 is localized to the p53 promoter, increasing tran-
scription of this gene and contributing to the increase in p53
protein levels after DNA damage (Bruno et al., 2006).
Mutant p53 proteins (mtp53) are abundantly present in cancer
cells of various histotypes (Soussi, 2000), where they show
oncogenic properties (Vousden and Lu, 2002). One common
mechanism underlying this ‘‘gain of function’’ is through
protein-protein interaction between mtp53 and other cellular
proteins, leading to the disruption of the normal functions of
these molecules. Indeed, some mtp53 proteins can interact
with and inhibit the transcriptionally active forms of the p53
homologs p73 and p63, leading to reduced apoptotic response
and chemoresistance (Li and Prives, 2007). More recently, it hasin human cancer.Mutant p53 proteins not only losewild-type
tributing to tumor aggressiveness and chemoresistance and
53 is considered a target for specific anticancer treatments.
ases mutant p53 expression in human cancer cells. In addi-
by activating DNA damage checkpoint in these cells. These
ltaneous modulation of p73 and mutant p53 levels. This
tumors harboring p53 mutations.
Figure 1. Che-1 Regulates Mutant p53
Expression
(A) Total cell extracts (TCEs) from the indicated cell
lines were subjected to chromatin immunoprecip-
itation (ChIP) with anti-Che-1 antibody (Ab). Immu-
noprecipitates from each sample were analyzed
by PCR and a sample representing linear amplifi-
cation (0.2–0.4 ml) of the total input chromatin
(input) was included in the PCRs as a control.
Additional control included a precipitation per-
formed with nonspecific IgGs.
(B) Western blot (WB) analysis of TCEs from the
indicated cell lines.
(C and D) SKBR3 cells were transiently transfected
with siRNA GFP (siControl) or two different siRNA
Che-1 (siChe-1-1 and siChe-1-2) and 24 hr later
total RNA and proteins were extracted. (C) RT-
PCR analysis of the indicated genes. (D) WB with
the indicated Abs. See also Table S1.
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Che-1 Regulates Mutant p53 Expressionbeen demonstrated that some mtp53 physically interact with
Mre11, a protein involved in DNA damage response, generating
genetic instability by ATM pathway inactivation (Song et al.,
2007). Finally, although most of mtp53 do not directly bind
DNA, several findings indicate that these proteins can exert their
oncogenic activity by an aberrant transcriptional activity (Strano
et al., 2007).
Mtp53 molecules are characterized by a prolonged half-life
compared with that of the wt-p53 protein and by the inability to
recognize specific DNA binding sites (Sigal and Rotter, 2000).
The molecular basis of the extended half-life of mtp53 proteins
might depend on the inefficient degradation exerted by MDM2,
a direct transcriptional target of wt-p53 (Haupt et al., 1997), but
also on the fact that in many tumors mtp53 might be stabilized
by DNA damage response pathways (Bartkova et al., 2005;
Gorgoulis et al., 2005).
Taken together, these observations suggest mtp53 as a target
for specific anticancer treatments. Indeed, a number of strate-
gies for targeting mtp53 have been designed, for example
peptides and small molecules that restore active conformation
and DNA binding to mtp53 (Selivanova and Wiman, 2007), or
disrupt the protein complex mtp53/p73 (Di Agostino et al.,Cancer Cell 18, 122–1342008). In addition, depletion of mtp53 by
RNA interference renders tumor cells
more sensitive to anticancer drugs and
reduces tumor malignancy in vitro and
in vivo (Bossi et al., 2006; Bossi et al.,
2008). Thus, we asked whether Che-1
also regulates mtp53 expression, and
whether Che-1 inhibition could affect pro-
liferation of cancer cells carrying mtp53.
RESULTS
Che-1 Regulates Mutant p53
Expression
In response to DNA damage Che-1 is
recruited onto the p53 promoter, and in
such a way contributes to an increase ofwt-p53 expression (Bruno et al., 2006). Thus, we hypothesized
that mtp53 expression might also be regulated by Che-1. To
test this possibility, we first investigated the presence of Che-1
onto the p53 promoter by performing chromatin immunoprecip-
itations (ChIP) in cancer cell lines carrying different mutants of
p53 (Table S1 available online) and analyzing the NF-kB binding
region of the TP53 promoter (Bruno et al., 2006). As shown in
Figure 1A, ChIP analysis revealed Che-1 physically associated
with the p53 promoter in SKBR3 and MDA-MB468 cells,
whereas it was barely detectable in primary breast epithelial
MCF10A cells. In addition, Che-1 protein was found accumu-
lated in cancer cells with respect to levels observed in normal
MCF10A cells (Figure 1B). Next, we tested the effects of Che-1
depletion on mtp53 expression. For this purpose SKBR3 cells
were transfected with two independent siRNA duplexes specific
for Che-1 sequences or with siRNA oligos specific for the green
florescent protein (GFP) as negative control. Efficient depletion
of Che-1 strongly decreased mtp53 expression both at the level
of mRNA (Figure 1C) and at the level of protein (Figure 1D) when
compared to control siRNA, and similar results were obtained
depleting Che-1 expression by another specific siRNA duplex
(not shown). Taken together, these results show that in cancer, August 17, 2010 ª2010 Elsevier Inc. 123
Figure 2. Che-1 Depletion Induces Apoptosis in Cells Expressing mtp53
(A) Indicated cell lines were transiently transfected with siRNA GFP () or siRNA Che-1 (+) and 24 hr later TCEs were analyzed by WB with the indicated Abs.
(B) MCF10A, SKBR3, andMDA-MB468 cells were transfected as in (A). Twenty-four hours later, cell death was assayed by trypan blue staining, and percentages
represent trypan blue incorporating cells. Data are presented as the mean ± SD from three independent experiments performed in duplicate.
(C and D) TCEs from the indicated cell lines transiently transfected as in (A), were subjected to WB with the indicated Abs.
(E) SKBR3 and MDA-MB468 cells were transiently transfected with siRNA GFP (siControl), siRNA Che-1 (siChe-1), or siChe-1 and mtp53 R175H (SKBR3) or
R273H (MDA-MB468) expression vectors. WB analysis of TCEs with the indicated Abs is shown on the left. Cell death analysis performed by trypan blue staining
as in (B) is shown on the right. Data are presented as the mean ± SD from three independent experiments performed in duplicate.
(F) TUNEL assay of SKBR3 andMDA-MB468 cells transfected as in (E). Shown on the top are representative fields of TUNEL-positive nuclei. The scale bar repre-
sents 100 mm. As shown on the bottom, TUNEL positivity is presented as the percentage of positive nuclei to total cell number. The data represent the mean ± SD
from three independent experiments.
Cancer Cell
Che-1 Regulates Mutant p53 Expressioncells carrying mtp53, Che-1 is present onto the p53 promoter
and is required for its expression.
Che-1 Depletion Induces Apoptosis in Cells Expressing
mtp53
To validate the results observed in SKBR3 cells, we tested
the effect of Che-1 depletion by siRNA in other cancer cell lines
expressing different mtp53 (Table S1). As shown in Figure 2A,
Che-1 inhibition strongly decreasedmtp53 protein levels in these
cells, confirming that Che-1 regulates the expression of this
gene. Strikingly, Che-1 depletion induced extensive cell death
in all cell lines expressing mtp53 (Figures 2A and 2B), and cell
death was accompanied by cleavage of the poly(ADP-ribosylat-
ing) enzymePARP-1, a specific hallmark of apoptosis (Figure 2A).
In contrast, depletion of Che-1 in MCF10A cells did not induce124 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.PARP-1 cleavage, or cause cell death (Figures 2A and 2B).
Notably, ZR75-1, a cancer cell line expressing wt-p53, did
not show apoptosis when Che-1 expression was inhibited (Fig-
ure 2A), and similar effects were observed in MDA-MB231,
a cancer cell line carrying mtp53, but in which Che-1 depletion
did not affect p53 levels, probably because of its elevated stabi-
lization in these cells (Figure 2C). Consistent with these results,
Che-1 downregulation did not induce PARP-1 cleavage in
p53/ H1299 cells (Figure 2D). To test whether Che-1 depletion
induces apoptosis by downregulating mtp53, we depleted
Che-1 inSKBR3andMDA-MB468cells in absenceor inpresence
of specific mtp53 overexpression (see Table S1). As shown
in Figures 2E and 2F, ectopic mtp53 expression rescued
apoptosis induced in Che-1 depleted cells. In addition, HT29,
a colon cancer cell line expressing R273H mtp53, exhibited p53
Figure 3. Che-1 Depletion Induces Puma and Noxa Expression
(A) Real-time QRT-PCR for candidate pro-apoptotic genes was performed after transient transfection of SKBR3 cells with siRNA GFP (siControl) or siRNA Che-1
(siChe-1). Values were normalized to GAPDH expression. Error bars represent the standard error of three independent experiments.
(B) Equal amounts of RNA (RNA input) from the indicated cell lines transfected as in (A) were analyzed by RT-PCR (25–30 cycles) for the expression of the indi-
cated genes. The negative control lanes represent RT-PCR in the absence of cDNA.
(C) MCF10A, SKBR3, and MDA-MB468 cells were transiently transfected as in (A) and after 24 hr or 36 hr TCEs were analyzed by WB with the indicated Abs.
(D) SKBR3 cells were transiently transfectedwith siRNAGFP (siControl), siRNAChe-1 (siChe-1), or siRNA p53 (sip53). WB analysis of TCEswith the indicated Abs
is shown on the top. Cell death analysis assayed by trypan blue staining is shown on the bottom. Percentages represent trypan blue incorporating cells. Data are
presented as the mean ± SD from three independent experiments performed in duplicate.
(E) TUNEL assay of SKBR3 cells transfected as in (D). Representative fields of TUNEL-positive nuclei are shown on the top. The scale bar represents 100 mm.
As shown on the bottom, TUNEL positivity is presented as the percentage of positive nuclei to total cell number. The data represent the mean ± SD from three
independent experiments. See also Figure S1.
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Che-1 Regulates Mutant p53 Expressiondecrease and cell death in response to Che-1 depletion,
but apoptosis was counteracted by mtp53 overexpression
(not shown). Altogether, these results show that Che-1 inhibi-
tion induces apoptosis in cancer cells by suppressing mtp53
expression.
Che-1 Depletion Induces Puma and Noxa Expression
Next, we investigated the mechanism/s by which Che-1
depletion induces apoptosis. We initially assayed by real-time
quantitative reverse transcriptase-polymerase chain reaction
(QRT-PCR) (the expression of well-characterized apoptotic
genes (Bax, Noxa, p53AIP1, Puma, and Pig3) in SKBR3 cells
after Che-1 depletion. From this analysis, it was observed thatPuma and Noxa, but no other proapoptotic genes, were induced
by Che-1 depletion (Figure 3A). Accordingly, Che-1 depletion
activated Puma promoter in SKBR3 and in MDA-MB468 cells,
whereas no induction was observed in MCF10A or ZR75-1 cells
(Figure S1A). In contrast, no induction of the Pig3 promoter was
found in any cell line analyzed (Figure S1B). Puma and Noxa acti-
vation in response to Che-1 depletion was further confirmed by
reverse transcriptase-polymerase chain reaction (RT-PCR) in
SKBR3 and in MDA-MB468 cells (Figure 3B), and in these cells,
unlike in MCF10A cells, the increase of Puma protein within
24 hr corresponded with PARP-1 cleavage (Figure 3C). Strik-
ingly, specific mtp53 depletion in SKBR3 cells by siRNA did
not produce Puma activation, PARP-1 cleavage (Figure 3D) orCancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc. 125
Figure 4. Che-1 Inhibition Activates p73 Expression
(A) Indicated cells were transiently transfected with siRNA GFP () or siRNA Che-1 (+). Cells were then subjected to ChIP with anti-p73 Ab or control IgGs.
(B) Equal amounts of RNA (RNA input) from indicated cells transfected as in (A) were analyzed byRT-PCR (25–30 cycles) for the expression of the indicated genes.
(C) TCEs from indicated cells transiently transfected as in (A) were analyzed by WB with the indicated Abs.
(D) SKBR3 cells were transiently transfected with siRNA GFP (siControl), siRNA Che-1 (siChe-1), or siChe-1 and siRNA p73 (sip73). WB analysis of TCEs with the
indicated Abs is shown on the top. Cell death analysis assayed by trypan blue staining is shown on the bottom. Percentages represent trypan blue incorporating
cells. Data are presented as the mean ± SD from three independent experiments performed in duplicate.
(E) TUNEL assay of SKBR3 cells transfected as in (D). Representative fields of TUNEL-positive nuclei are shown on the top. The scale bar represents 100 mm.
As shown on the bottom, TUNEL positivity is presented as the percentage of positive nuclei to total cell number. The data represent the mean ± SD from three
independent experiments. See also Figure S2.
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Che-1 Regulates Mutant p53 Expressionapoptosis (Figures 3D and 3E), suggesting that mtp53 depletion
is required but not sufficient for apoptosis induction. Thus,
specific Che-1 depletion in mtp53 expressing cells leads to
induction of proapototic effector genes, PARP-1 cleavage, and
cell death.
Che-1 Depletion Activates p73 Expression
Several findings support the hypothesis that mtp53 promotes
pro-oncogenic activities by sequestering and inactivating the
p53 homologs p63 and p73 (Blandino et al., 1999; Di Como
et al., 1999; Gaiddon et al., 2001; Strano et al., 2002; Li and
Prives, 2007). Given that Puma is a specific p73 target gene
(Ramadan et al., 2005; Melino et al., 2004), we hypothesized
that Che-1 depletion might promote apoptosis through activa-
tion of p73. We first tested on Che-1 depletion, the presence
of p73 onto the Puma promoter by ChIP analysis in SKBR3,126 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.MDA-MB468 and MCF10A cells. As is shown in Figure 4A,
Che-1 depletion produced a strong recruitment of p73 onto the
p53 family binding site of the Puma promoter in SKBR3 and
MDA-MB468 cells, whereas this effect was not observed in
MCF10A cells. According to the literature, p73 accumulation
onto the Puma promoter might depend on the decrease of
mtp53 levels, that, reducing p73 sequestration, allows the resto-
ration of p73 transcriptional effects (Li and Prives, 2007).
However, we did not observe a significant increase of overex-
pressed p73 activity in Che-1 depleted cells (Figure S2A), sug-
gesting an involvement of some other mechanism. Thus, we
examined whether Che-1 depletion induces p73 expression.
Consistent with this hypothesis, RT-PCR analysis revealed an
increase of p73 mRNA levels after Che-1 depletion in either
SKBR3 or MDA-MB468 cells, but not in MCF10A cells (Fig-
ure 4B). Accordingly, several cell lines carrying mtp53 exhibited
Cancer Cell
Che-1 Regulates Mutant p53 Expressiona strong increase of p73 protein level upon Che-1 depletion (Fig-
ure 4C). In addition, the use of peptides that specifically disrupt
the mtp53/p73 complex (Di Agostino et al., 2008), enhanced
apoptosis induced by Che-1 depletion in SKBR3 cells (Figures
S2B and S2C). To test directly whether endogenous p73 is
required for cell death induced by Che-1 depletion, we investi-
gated the effects of Che-1 inhibition in cells in which p73
expression was ablated by RNAi. Remarkably, p73 depletion
substantially and consistently abrogated the effects of Che-1
inhibition. Indeed, in absence of p73 little or no Puma induction,
PARP-1 cleavage or apoptosis were observed (Figures 4D
and 4E). Therefore, p73 is required for the apoptotic program
elicited after loss of Che-1. Altogether, Che-1 inhibition induces
apoptosis not only by decreasing mtp53 levels, but also by
increasing p73 expression.
Che-1 Depletion Induces DNA Damage Response
Next, we investigated the mechanism/s by which Che-1 deple-
tion increases p73 levels in cancer cells expressing mtp53.
Several findings have demonstrated that in response to DNA
damage, the E2F1 transcription factor is stabilized by checkpoint
activation (Lin et al., 2001; Urist et al., 2004) and recruited onto
the p73 promoter (Pediconi et al., 2003; Urist et al., 2004; Irwin
et al., 2000; Lissy et al., 2000; Stiewe and Putzer, 2000). Because
recent studies have revealed a specific gain of function of mtp53
in inducing genetic instability by inactivating critical checkpoint
activation pathways (Song et al., 2007), we evaluated whether
Che-1 knockdown might induce checkpoint activation in cancer
cells expressing mtp53. As shown in Figure 5A, Che-1 depletion
induced a specific increase of checkpoint activation in several
cancer cells expressing mtp53, evaluated by western blot anal-
ysis of phosphorylated levels of histone H2AX, ATM, and Chk2
(Rogakou et al., 1998; Pilch et al., 2003; Bakkenist and Kastan,
2003; Ahn et al., 2002). Consistent with these findings, confocal
microscopy imaging analysis using antibodies for phosphory-
lated forms of histone H2AX and ATM indicated a massive
DNA damage foci formation after Che-1 depletion (Figure S3A).
Moreover, in line with the results of Song et al. (2007), Mre11
was also found recruited in DNA damage foci (Figure S3A). Of
note, Che-1 inhibition did not induce histone H2AX phosphoryla-
tion in ZR75-1 orMDA-MB231 cells (not shown). This checkpoint
activation was also observed in presence of Z-Vad, a caspase
inhibitor (Figure S3B), thereby excluding an activation from
apoptotic DNA fragmentation. Notably, Che-1 depletion induced
E2F1 stabilization in MDA-MB468 cells, associated with phos-
phorylation of histone H2AX (Figure 5B). Consistent with these
results, Che-1 inhibition strongly increased the presence of
E2F1 onto the p73 promoter in SKBR3 and MDA-MB468 cells
(Figure 5C). To evaluate whether E2F1 is directly involved in
p73 activation after Che-1 depletion, we tested the effect of
Che-1 inhibition in SKBR3 cells depleted of E2F1 expression.
Although histone H2AX phosphorylation was still observed in
these cells (Figure 5D), loss of E2F1 prevented p73 and Puma
activation, PARP-1 cleavage and cell death (Figure 5D and
Figure S4C). Notably, mtp53 expression rescued Puma expres-
sion induced by Che-1 depletion, although in these cells DNA
damage was induced and p73 expression increased (Fig-
ure 5E). In accordance with these findings, mtp53 overexpres-
sion did not allow p73 recruitment onto the Puma promoterand its transcription (Figures 5F and 5G). Taken together, these
results indicate that Che-1 depletion in tumor cells carrying
mtp53 induces p73 activation through E2F1 stabilization and
checkpoint activation, but does not affect Puma expression
and apoptosis if mtp53 expression is not inhibited.
Che-1 Is Involved in DNA Repair
The data described above demonstrate that Che-1 inhibition
induces checkpoint activation and E2F1 stabilization in SKBR3
and MDA-MB468 cells. To shed light on the mechanism/s by
which these effects are exerted, we evaluated cell cycle profiles
of Che-1-depleted MDA-MB468 and MCF10A cells 12 hr after
siRNA transfection, before induction of the apoptotic process
(Figure 3C). As shown in Figure 6A, MDA-MB468 Che-1-
knocked down cells exhibited a cell cycle profile with a strong
G2/M depletion and a concomitant S phase accumulation.
In addition, Che-1 depleted cells showed a reduced bromodeox-
yuridine incorporation (Figure S4A), thus suggesting a specific
replication-associated damage and inhibition of S phase
progression. Similar results were observed in SKBR3 cells (not
shown). Given that Che-1 is a RNAPol II-binding protein involved
in gene transcription, to understand the biological relevance of
Che-1 in these phenomena, we took advantage of a high-density
Affimetrix microarray analysis performed using SKBR3 cells
transiently transfected with control siRNA or Che-1 siRNA
(Figure S4B). In agreement with Che-1 antiapoptotic activity
(Passananti et al., 2007; Bruno et al., 2008), several proapoptotic
genes were found to be induced by Che-1 depletion (Fig-
ure S4C). Interestingly, among the downregulated genes in
Che-1-depleted cells we identified several genes involved in
DNA damage response and DNA repair (Figure S4C), and
consistent with these findings, Che-1 depletion strongly reduced
the repair of damaged DNA (Figure S4D). In particular, we found
that loss of Che-1 downregulated Bloom syndrome helicase
(BLM) and RAD17, whose role in intra-S phase checkpoint is
well established (Amor-Gue´ret, 2006; Wu, 2007; Wang et al.,
2006). These microarray data were confirmed by another
microarray analysis performed in Che-1 depleted MDA-MB468
cells, and by RT-PCR (Figure 6B and Figure S5E), but expression
of these genes was not found modulated by Che-1 RNAi
in MCF10A control cells (Figure 6C). Furthermore, western blot
analysis showed a significant reduction of BLM and RAD17
protein levels in MDA-MB468, SKBR3 and TD47 cells (Fig-
ure 6C). Interestingly, in H1299 cells stably expressing mtp53,
increased levels of both BLM and RAD17 were observed
(Figure S4F). To evaluate whether apoptosis after Che-1 inhibi-
tion involves BLM and RAD17 downregulation, we depleted
Che-1 in SKBR3 cells in absence or in presence of BLM and
RAD17 overexpression. Strikingly, restoration of BLM and
RAD17 protein levels counteracted DNA damage and apoptosis
induced by Che-1 ablation (Figure 6D and Figure S4G), In addi-
tion, whereas BLM depletion produced DNA damage but did
not induce apoptosis, a simultaneous depletion of mutant p53
and BLM expression recapitulated the effects observed when
Che-1 expression is inhibited, inducing DNA damage, p73
expression and apoptosis (Figure 6E and Figure S4H). Taken
together, these results strongly support an involvement of
Che-1 in DNA repair and indicate that its depletion induces repli-
cation stress in cancer cells with mutated p53.Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc. 127
Figure 5. Che-1 Depletion Induces DNA Damage Response
(A) Indicated cells were transiently transfected with siRNA GFP () or siRNA Che-1 (+). TCEs were analyzed by WB with the indicated Abs.
(B) MDA-MB468 cells were transfected as in (A) and after 24 hr or 36 hr TCEs were analyzed by WB using the indicated Abs.
(C) Indicated cells were transiently transfected with siRNA GFP () or siRNA Che-1 (+). Cells were then subjected to ChIP using anti-E2F1 Ab or control IgGs.
(D) SKBR3 cells were transiently transfected with siRNA GFP (siControl), siRNA Che-1 (siChe-1), or siChe-1 and siRNA E2F1 (siE2F1). WB analysis of TCEs with
the indicated Abs is shown on the left. Cell death analysis assayed by trypan blue staining is shown on the right. Percentages represent trypan blue incorporating
cells. Data are presented as the mean ± SD from three independent experiments performed in duplicate.
(E) SKBR3 cells were transiently transfected with siRNA GFP (siControl), siRNA Che-1 (siChe-1), or siChe-1 and mtp53 R175H expression vector. WB analysis of
TCEs was performed with the indicated Abs.
(F) SKBR3 cells were transfected as in (E) and subjected to ChIP with anti-p73 Ab or control IgGs.
(G) Equal amounts of RNA (RNA input) from SKBR3 cells transfected as in (E) were analyzed by RT-PCR (25–30 cycles) for the expression of the indicated genes.
See also Figure S3.
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Che-1 Regulates Mutant p53 ExpressionChe-1 Depletion Suppresses Tumor Growth in a Mouse
Xenograft Model
The results described above indicate that Che-1 is required
to sustain mtp53 expression and to maintain cell survival.
To further confirm these data, under more physiologic condi-
tions, we generated an in vivo conditional RNAi model. To this
aim, we produced a stable conditional depletion of Che-1 by
infecting MDA-MB468 cells with either an inducible lentiviral
vector carrying a specific hairpin (sh) RNA against Che-1
(MDA-MB468 ind-si/Che-1) or with a vector carrying a control128 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.hairpin (MDA-MB468 ind-si/Control) (Bossi et al., 2006). As
shown in Figure 7A, depletion of Che-1 by doxycycline (Dox)
treatment decreased mtp53, and increased PARP-1 cleavage.
Moreover, when MDA-MB468 ind-si/Che-1 cells were treated
with Dox, they exhibited DNA damage induction, with subse-
quent stabilization of E2F1 and activation of p73 and Puma
(Figure 7B). Therefore, to perform studies in vivo, either ind-si/
Che-1 or ind-si/Control engineered cells were implanted subcu-
taneously in Scid/Scid immunodepleted mice. Three weeks
after injection, when injected cells generated tumor nodules
Figure 6. Che-1 Is Involved in DNA Repair
(A)MCF10A andMDA-MB468 cells were transiently transfected with siRNAGFP (siControl) or siRNAChe-1 (siChe-1). After 12 hr, cells were fixed and stainedwith
propidium iodide (PI) and analyzed for DNA content.
(B) RT-PCR analysis of expression of the indicated genes from MCF10A and SKBR3 cells transiently transfected with siRNA GFP () or siRNA Che-1 (+).
(C) WB analysis with the indicated Abs of TCEs from the indicated cells transfected as in (B).
(D) SKBR3 cells were transiently transfected with siRNAGFP (siControl), siRNAChe-1 (siChe-1), or siChe-1 andBLMandRAD17 expression vectors.WB analysis
of TCEs with the indicated Abs is shown on the left. Cell death analysis assayed by trypan blue staining is shown on the right. Percentages represent trypan blue
incorporating cells. Data are presented as the mean ± SD from three independent experiments performed in duplicate.
(E) SKBR3 cells were transiently transfected with the indicated siRNA. WB analysis of TCEs with the indicated Abs is shown on the left. Cell death analysis
assayed by trypan blue staining is shown on the right. Percentages represent trypan blue incorporating cells. Data are presented as the mean ± SD from three
independent experiments performed in duplicate. See also Figure S4.
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Che-1 Regulates Mutant p53 Expression(0.2 cm3), animals were subdivided into groups and either
treated or untreated with Dox (2.0 g/l) for 5 weeks. At the end
of treatments, all the animals were sacrificed and tumor excited.
Although similar experiments showed that mtp53 depletion
reduces tumor growth ability and chemoresistance (Bossi
et al., 2008), results from this analysis showed that with respect
to control animals (ind-si/Che-1 – Dox, ind-si/Control +/ Dox)
ablation of Che-1 protein deeply impacts on tumor growth,
producing a complete remission of formed tumor (Figures 7C
and 7D). Histological examination of excised tumors revealed
that induced Che-1 depletion displayed ample necrosis, scarred
tissue and scanty mononuclear cell infiltrates respect to ind-si/
Che-1 – Dox and ind-si/Control +/ Dox control tumors (Fig-
ure 7E). Hence, abrogation of Che-1 expression by RNAi
completely inhibited MDA-MB468 tumor malignancy and
strongly suggests Che-1 as a possible antineoplastic therapeutic
target.DISCUSSION
The gain of function of mtp53 promotes tumor formation and
drug resistance, contributing to the poor prognosis of cancer
patients. Therefore, several therapeutic rationales targeting
mt53 activity are currently under investigation including attempts
to inhibit mtp53 expression. In the present study, we provide
evidence that Che-1 is required for mtp53 expression in human
cancer cells, and that its depletion induces a specific apoptotic
program in these cells.
We have previously reported that in response to DNA damage,
Che-1 is stabilized and promotes wild-type p53 gene transcrip-
tion, contributing to the maintenance of the G2/M checkpoint
(Bruno et al., 2006). Here we show that Che-1 is required for
mtp53 expression in several human cancer cell lines, and in
such a way can contribute to mtp53 ‘‘gain of function.’’ Further-
more, inhibition of Che-1 leads to DNA damage-dependent p73Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc. 129
Figure 7. Che-1 Depletion Suppresses Tumor Growth in a Mouse Xenograft Model
(A) MDA-MB468 cells were infectedwith LV-THsh/Che-1 (siChe-1) or LV-THsh/Control (siControl) and LV-tTR-KRAB lentiviruses. Formonitoring inducible shRNA
expression, different concentrations of doxycycline (Dox) were added to the cell medium. Five days later, cells were harvested and processed for WB analysis
with the indicated Abs.
(B) TCEs from MDA-MB468 cells induced (+Dox) or not (Dox) were analyzed by WB with the indicated Abs.
(C) Engineered MDA-MB468 ind-siChe-1 and MDA-MB468 ind-siControl cell lines were implanted into subcutaneous of Scid/Scidmice, and animals treated as
reported (see Experimental Procedures). Animals were monitored weekly as reported in Experimental Procedures. Data are presented as the mean ± SD from
three independent experiments performed with different groups of ten mice.
(D) Representative mice (top) or excised tumors (bottom) from induced (+Dox) or not (Dox) MDA-MB468 ind-siChe-1 andMDA-MB468 ind-siControl implanted
cells.
(E) Sections of tumors from mice injected and treated as in (C) were stained with hematoxylin and eosin. The scale bar represents 100 mm.
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Che-1 Regulates Mutant p53 Expressionactivation and apoptosis. We also show that Che-1 is not only
a component of DNA damage response, but is involved in DNA
repair mechanisms, regulating the expression of important
genes such as BLM and RAD17, suggesting that cancer cells
carrying mtp53 require these proteins to proliferate. Finally, we
provide evidence that the constitutive deregulation of Che-1
abolishes the tumorigenicity of cancer cells in an animal model.
Our results report that Che-1 is accumulated and recruited
onto the p53 promoter in cancer cells but not in primary breast
fibroblasts (Figures 1A and 1B). These findings are in agreement
with the notion that DNA damage response is, at least in part,
chronically activated in human cancer cells (Bartkova et al.,
2005; Gorgoulis et al., 2005). Moreover, several reports have
described an induction of genetic instability by gain of function130 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.mtp53 (Murphy et al., 2000; Murphy and Rosen, 2000; Song
et al., 2007), that might induce Che-1 stabilization and thereby
activation of p53 expression.
We show that inhibition of Che-1 by siRNA strongly decreases
mtp53 levels in several cancer cell lines. This effect is essentially
due to transcriptional control of p53 by Che-1 (Figure 1C) but we
cannot exclude the possibility that Che-1 might exert a transla-
tional control of p53 expression. Notably, ablating Che-1 expres-
sion triggers induction of Puma and apoptotic cell death.
These events were not observed when mtp53 was depleted,
leading to the hypothesis that apoptosis is activated by other
mechanism/s. Nevertheless, although Che-1 exhibits an anti-
apoptotic activity, its depletion did not trigger apoptosis in
normal cells or in tumor cells carrying either wtp53 or lacking
Figure 8. Model to Explain the Effects of Che-1 Depletion in Breast
Cancer Cells Carrying Mutant p53
Che-1 inhibition decreases mutant p53 cellular levels weakening its gain of
function. In addition, loss of Che-1 produces downregulation of important
genes involved in replication checkpoint such as BLM and RAD17. This results
in activation of DNA damage response, E2F1 stabilization, and transactivation
of p73. Therefore, simultaneous modulation of p73 and mutant p53 levels
allows the recruitment of p73 onto proapoptotic gene promoters and induces
cell death.
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Che-1 Regulates Mutant p53 Expressionp53 expression, thereby suggesting that this phenomenon
requires mtp53 downregulation. Accordingly, Che-1 RNAi in
MDA-MB231 cells did not induce either mtp53 inhibition or
apoptosis, and mtp53 overexpression rescued apoptosis in
Che-1-depleted SKBR3 and MDA-MB468 cells.
Our findings demonstrate that Che-1 inhibition induces p73
transactivation and its recruitment on the Puma promoter. This
activity is required for induction of apoptosis. Relocalization of
p73, Puma induction and PARP-1 cleavage all occur within
24 hr of siRNA transfection. This interval presumably reflects
the time necessary for Che-1 and mtp53 degradation, for p73
transactivation and its release from mtp53/p73 complex, and
finally for assembly of an active p73 complex at the Puma
promoter. Therefore, it is reasonable to speculate that p73-medi-
ated cell death after Che-1 depletion may represent the cumula-
tive effects of increased p73 levels and concomitant decreased
mutant p53- mediated inhibition.
It has been previously demonstrated that p73 is regulated in
response to DNA damage through Chk1- and Chk2-mediated
E2F1 activation and stabilization (Gonzalez et al., 2003; Urist
et al., 2004; Pediconi et al., 2003). Accordingly, here we show
that Che-1 depletion in tumor cells expressing mtp53 induces
endogenous checkpoint activation, E2F1 stabilization, and its
relocalization onto p73 promoter. In addition, Che-1 overexpres-
sion was found to strongly inhibit E2F1-mediated p73 transacti-
vation (not shown). Given that Che-1 binds the E2F1 complex in
a proliferative pathway (Bruno et al., 2002), it might also be
possible that Che-1 RNAi induces the release of E2F1 from cell
cycle promoters, allowing its accumulation on the p73 promoter.
Recent findings have indicated that mutant forms of p53
can inactivate critical DNA damage-response pathways, by
removing the MRN complex from DNA double strand breaks
(Song et al., 2007). Thus, it is possible that downregulating
mtp53 expression, Che-1 depletion restores a functional check-
point activation and apoptosis. Nevertheless, the observation
that MDA-MB468 Che-1 depleted cells exhibit S phase accumu-
lation and a reduced BrdU incorporation, suggests that DNA
replication stress might be involved. Consistent with this hypoth-
esis, Che-1 was found to regulate transcription of several genes
involved in DNA repair and DNA damage response. Interestingly,
among the Che-1-regulated genes, we identified BLM and
RAD 17, whose role in response to DNA replication stress is
well established (Wu, 2007; Wang et al., 2006). In agreement
with genomic instability observed in tumor cell expressing
mtp53, we found increased levels of BLM and RAD17 proteins
in these cells (Figure 6C) and in p53/ H1299 cells stably over-
expressing mtp53 (Figure S4F). Che-1 inhibition decreased
expression of these genes at both RNA and protein level, and
additional experimental data will providemore evidence to better
characterize the mechanisms by which Che-1 regulates the
transcription of these genes. Of note, Bloom’s syndrome cells
exhibit endogenous checkpoint activation related to DNA
replication abnormalities (Rassool et al., 2003; Li et al., 2004;
Rao et al., 2007), and BLM/RAD17 double knockout chicken
DT 40 cells showed an increased rate of DNA lesions that
cause spontaneous cell death (Nishino et al., 2008). Strikingly,
restoration of BLM and RAD17 expression in Che-1 depleted
cancer cells almost completely reverted DNA damage and
apoptotic program induced by Che-1 depletion (Figure 6D andFigure S4G), whereas simultaneous depletion of BLM and
mtp53 induced DNA damage and apoptotic process (Figure 6E
and Figure S4H). Together, our findings enable us to propose
a model in which Che-1 is required for ensuring expression of
both gain of function mtp53, and at the same time BLM and
RAD17, for allowing cell proliferation, even in the presence of
genomic instability (Figure 8). Therefore, although mtp53 knock-
down reduces resistance to anticancer drugs (Bossi et al., 2006;
Bossi et al., 2008), Che-1 depletion induces apoptosis without
any genotoxic treatment (Figure 8). Consistent with this model,
in vivo experiments performed by an inducible RNAi system
demonstrate that conditional depletion of Che-1 deeply impacts
on tumor growth, thereby identifying a therapeutic approach
that, through allowing simultaneous modulation of p73 and
mtp53 levels, might be used to target the large fraction of human
tumors that harbor p53 mutations.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Analysis
SKBR3, MDA-MB468, MDA-MB231, BT549, T47D, and ZR75-1 breast cancer
cell lines were all cultured in RPM1 1640 with 10% fetal calf serum. H1299
human lung carcinoma cells and 293T packaging cells, kindly provided by
Dr. S. Iacovelli were cultured in D-MEM high glucose with 10% FBS.
MCF10A primary breast epithelial cells (a gift from Dr. Segatto) were cultured
in Ham’s F-12 medium with 5% horse serum, 0.5 mg/ml hydrocortisone,
10 mg/ml insulin, and 20 ng/ml EGF. Cytofluorimetric analysis of cellular
DNA content was performed on propidium iodide stained cells by an Epics
XL Analyzer (Coulter Corporation). The following plasmids were used in
transfection experiments: pcDNA3-BLM (kindly provided by Dr. I.D. Hickson),
pcDNA3-RAD17 (a gift fromDr. P. Perego), pcDNA3-p53His175, and pcDNA3-
p53His273 (Strano et al., 2000). Transfections were carried out by Lipofect-
amine Plus (Invitrogen) following the manufacturer’s instructions. TUNEL
assays were performed by using TUNEL Apoptosis Detection Kit (Millipore)
following the manufacturer’s instructions.
Cell Extracts and Western Blot
Cell extracts were prepared as previously described (Bruno et al., 2006). Solu-
bilized proteins (25 mg) were resolved onMopsNuPAGEprecast 4%–12%gelsCancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc. 131
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Che-1 Regulates Mutant p53 Expression(Invitrogen). Western blotting was performed using the following rabbit poly-
clonal antibodies: anti-Che-1 (Fanciulli et al., 2000), PARP-1 p85 fragment
(Promega), p73 (Bethyl), Puma (Calbiochem), BLM (Cell Signaling), and
CHK2 phospho thr68 (Cell Signaling). Mouse monoclonal antibodies anti-
p53 (DO1), E2F1 KH95 (Santa Cruz), a-actin (Sigma), Rad17 (Santa Cruz),
ATM phospho ser1981 (Rockland), and gH2AX phospho ser139 (Upstate)
were also used. Secondary antibodies used were goat anti-mouse and goat
anti-rabbit, conjugated to horseradish peroxidase (BioRad). Immunostained
bands were detected by the chemiluminescent method (Amersham).
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation assays were performed as previously
described (Bruno et al., 2002) with the following rabbit polyclonal antibodies:
anti-Che-1, E2F1 C20 (Santa Cruz), and p73 (Bethyl). In each experiment,
signal linearity was ensured by amplifying increasing amounts of template
DNA. Generally, DNA representing from 0.005% to 0.01% of the total chro-
matin sample (input) or from 1% to 10% of the immunoprecipitated was ampli-
fied using promoter-specific primers. Immunoprecipitations with no specific
immunoglobulins (Santa Cruz) were performed as negative control.
RNA Isolation, QRT-PCR, and RT-PCR Analysis
Cells were harvested 36 hr after transfection and total RNA isolated using
TRIZOL reagent (Invitrogen) in accordance with the manufacturer’s instruc-
tions, and the first-strand cDNA was synthesized with the Thermo Script
RT-PCR kit (Invitrogen) in accordance with the manufacturer’s instructions.
Applied Biosystems 7500 system SDS software was used for real-time
PCR analysis. The analysis was performed with SYBR-green I fluorescence
(Applied Biosystems). Quantification of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) mRNA (as an internal control for gene expression in the cells)
was performed with TaqMan Human GAPDH Control Reagents (with VIC
Probe, Applied Biosystems).
For semiquantitative RT-PCR analysis, RT-PCR was performed with a Plat-
inum quantitative RT-PCR kit (Invitrogen) in accordance with the manufac-
turer’s instructions. PCR products were separated onto 1.5% agarose gel.
siRNA
The 22-nucleotide siRNA duplexes corresponded to nucleotides 1062–1083
and 1473–1492 of human Che-1 sequence, to nucleotides 773–794 of human
p53 sequence, and to nucleotides 122–143 of the negative control green fluo-
rescent protein (GFP) sequence were in vitro synthesized by Silencer siRNA
construction kit (Ambion) following manufacturer’s instruction. siRNA p73
duplexes were purchased from QIAGEN. RNA interference was performed
as previously described (Bruno et al., 2002). siRNA-mediated interference
experiments of E2F1 and BLM expression were performed by transfecting
SMART pool specific or nonspecific control pool double-stranded RNA oligo-
nucleotides (Millipore) using Lipofectamine Plus (Invitrogen).
Design and Cloning of shRNA
The following oligos were annealed and cloned in pLV-THM vector (Wiznero-
wicz and Trono, 2003) MluI/ClaI (Boehringer Mannheim, Germany) digested,
generating the new lentiviral vectors pLV-TH si/Che-1 and pLV-TH si/control.
Si/Che-1 oligo sequences (nucleotides 824–842): 50-gatccccAAAGTTTCT
GAGGAAGTGGttcaagagaCCACTTCCTCAGAAACTTTtttttggaaa-30 and 50- ag
cttttccaaaaaAAAGTTTCTGAGGAAGTGGtctcttgaaCCACTTCCTCAGAAACTT
Tggg-30.
Si/control oligo sequences: 50-cgcgtCTATAACGGCGCTCGATATttcaaga
gaATATCGAGCG-CCGTTATAGtttttggaaat-30 and 50-cgatttccaaaaaCTATAA
CGGCGCTCGATATtctcttgaaATA-TCGAGCGCCGTTATAGa-30.
Viral Vectors
Lentiviral vectors pLV-THM and pLV-tTR-KRAB (Wiznerowicz and Trono,
2003) were produced by transient transfection in 293T cells according to stan-
dard protocols (Zufferey et al., 1997). In brief, subconfluent 293T cells were
cotransfected with 20 mg of a plasmid vector, 15 mg of pAX2, and 6 mg
of pMD2G-VSVG by calcium phosphate precipitation (GIBCO-BRL). After
6–8 hr, medium was replaced with fresh medium (6.0 ml/plate) supplemented
with 1.0 mM Sodium Pyruvate (GIBCO-BRL). Lentiviruses were harvested
48 hr later, centrifuged 5 min at 3,000 RPM, aliquoted and stored at –80C.132 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.Lentiviral stocks were titered following standard protocols (Wiznerowicz and
Trono, 2003), and routinely a viral titer of 106 transducing units per ml was
achieved.
Cellular Transduction
For conditional RNA interference, MDA-MB468 cells were plated in 24-well
plate (3.0 3 104 cells/well). Sixteen hours later, medium containing LV-THsh/
Che-1 (indsi/Che-1) or LV-THsh/Control (indsi/control) and LV-tTR-KRAB
lentiviruses supplemented with 8.0 mg/ml of polybrene was added to the cells.
After 16 hr of incubation, cells were washed and replenished with fresh
medium. Ninty-six hours later part of the cells were processed for western
blot analysis. For monitoring shRNA expression upon doxycycline hydrochlo-
ride (Dox) (D9891, Sigma-Aldrich), the newly generated MDA-MB468-indsi/
Che-1 cells were plated and 24 hr later different concentrations of Dox were
added to the medium. Dox was added every 3 days. Five days later, cells
were harvested and processed for western blot analysis.
In Vivo Experiments
Forty-day-old immunodeficient Scid/Scid female mice (Charles River Labora-
tories, Lecco, Italy) in groups of ten were maintained in a sterile environment.
Engineered MDA-MB468 cells were injected (1.5 3 107 cells/mouse) with
Matrigel (BD Biosciences) in the intrascapular area. Doxycycline was delivered
to the mice through drinking water (tap water + 3.0% sucrose [Sigma]) in dark
stained bottles, and renewed every 4 days. MDA-MB468 xenograft tumor
growth delay was monitored twice a week by caliper measurements, tumors
volumes (TV [cm3]) were estimated by formula: TV = a 3 (b2)/2, where a and
b are tumor length and width respectively in cm. At the end of treatments
animal were sacrificed in accordance with standard protocols, tumors
excised, and sections frozen in liquid nitrogen. Sections were then conserved
at –80C for further analyses. All the procedures involving animals and their
care were approved by the Ethical Committee of the Regina Elena Cancer
Institute, (Prot. CE/572/07), and were conformed to the relevant regulatory
standards in accordance with the Italian legislation.ACCESSION NUMBERS
All microarray raw data tables have been deposited at the National Center for
Biotechnology Information (NCBI) Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo) under the accession number GSE20622 (submitter
M.F.).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one table, and four figures and can be found with this article online at
doi:10.1016/j.ccr.2010.05.027.
ACKNOWLEDGMENTS
This work is dedicated to the memory of Paolo Gardino. We thank Dr. Silvia
Soddu for fruitful discussions. We acknowledge Mrs. Geraldine Williams for
English revision. We thank Dr. Aymone Gurtner, Dr. Francesca Siepi, Mrs.
Rita Nicotra, Mrs. Annalisa Onori, and Mr. Marco Scarsella for their precious
assistance. We acknowledge Dr. Piergiorgio Natali for histological analysis.
This work was supported by the Italian Association for Cancer Research
(AIRC) (M.F., G.B., C.P., G.B.), the Ministero della Sanita` (M.F., G.B.), the
Alleanza Contro il Cancro (M.F.), MIUR-FIRB Italy, the European Community
(EC) Active p53 and Mutant p53 consortia (G.B.), Telethon-Italy (grant
GGP07177), the Ministero della Sanita`, by Paul Blu¨mel Stiftung fu¨r medizini-
sche Forschung (C.P.), and by MIUR ex 60% (A.F.). S.I. and F.D.N. are the
recipients of F.I.R.C. fellowships.
Received: June 17, 2009
Revised: April 6, 2010
Accepted: June 23, 2010
Published: August 16, 2010
Cancer Cell
Che-1 Regulates Mutant p53 ExpressionREFERENCES
Ahn, J.Y., Li, X., Davis, H.L., and Cancan, C.E. (2002). Phosphorylation of
threonine 68 promotes oligomerization and autophosphorylation of the Chk2
protein kinase via the forkhead-associated domain. J. Biol. Chem. 277,
19389–19395.
Amor-Gue´ret, M. (2006). Bloom syndrome, genomic instability and cancer:
The SOS-like hypothesis. Cancer Lett. 236, 1–12.
Bakkenist, C.J., and Kastan, M.B. (2003). DNA damage activates ATM through
intermolecular autophosphorylation and dimmer dissociation. Nature 421,
499–506.
Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., Guldberg, P.,
Sehested, M., Nesland, J.M., Lukas, C., et al. (2005). DNA damage response
as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434,
864–870.
Blandino, G., Levine, A., and Oren, M. (1999). Mutant p53 ‘‘gain of function’’:
Differential effects of different p53 mutants on resistance of cultured cells to
chemotherapy. Oncogene 18, 477–485.
Bossi, G., Lapi, E., Rinaldo, C., Blandino, G., and Sacchi, A. (2006). Mutant p53
‘‘gain of function’’: Reduction of tumor malignancy of human cancer cell lines
through abrogatin og mutant p53 expression. Oncogene 25, 304–309.
Bossi, G., Marampon, F., Maor-Aloni, R., Zani, B., Rotter, V., Oren, M., Strano,
S., Blandino, G., and Sacchi, A. (2008). Conditional RNA interference in vivo to
study mutant p53 oncogenic ‘‘gain of function’’ on tumor malignancy. Cell
Cycle 7, 1870–1879.
Bruno, T., De Angelis, R., De Nicola, F., Barbato, C., Di Padova, M., Corbi, N.,
Libri, V., Benassi, B., Mattei, E., Chersi, A., et al. (2002). Che-1 affects cell
growth by interfering with the recruitment of HDAC1 by Rb. Cancer Cell 2,
387–399.
Bruno, T., De Nicola, F., Iezzi, S., Lecis, D., D’Angelo, C., Di Padova, M., Corbi,
N., Dimiziani, L., Tannini, L., Jekimovs, C., et al. (2006). Che-1 phosphorylation
by ATM and Chk2 kinases activates p53 transcription and the G2/M check-
point. Cancer Cell 10, 473–486.
Bruno, T., Iezzi, S., De Nicola, F., Di Padova, M., Desantis, A., Scarsella, M., Di
Certo, M.G., Leonetti, C., Floridi, A., Passananti, C., and Fanciulli, M. (2008).
Che-1 activates XIAP expression in response to DNA damage. Cell Death
Differ. 15, 515–520.
Burgdorf, S., Leister, P., and Scheidtmann, K.H. (2004). TSG101 interacts with
AATF and enhances AR-mediated transcription by promoting its mono-ubiq-
uitination. J. Biol. Chem. 279, 17524–17534.
De Nicola, F., Bruno, T., Iezzi, S., Di Padova, M., Floridi, F., Passananti, C.,
Del Sal, G., and Fanciulli, M. (2007). The prolyl isomerase Pin1 affects
Che-1 stability in response to apoptotic DNA damage. J. Biol. Chem. 282,
19685–19691.
Di Agostino, S., Cortese, G.,Monti, O., Dell’Orso, S., Sacchi, A., Eisenstein,M.,
Citro, G., Strano, S., and Blandino, G. (2008). The disruption of the protein
complex mutantp53/p73 increases selectively the response of tumor cells to
anticancer drugs. Cell Cycle 7, 3440–3447.
Di Certo, M.G., Corbi, N., Bruno, T., Iezzi, S., De Nicola, F., Desantis, A., Ciotti,
M.T., Mattei, E., Floridi, A., Fanciulli, M., and Passananti, C. (2007). NRAGE
associates with the anti-apoptotic factor Che-1 and regulates its degradation
to induce cell death. J. Cell Sci. 120, 1852–1858.
Di Como, C.J., Gaiddon, C., and Prives, C. (1999). p73 function is inhibited by
tumor-derived p53mutants inmammalian cells. Mol. Cell. Biol. 19, 1438–1449.
Fanciulli, M., Bruno, T., Di Padova, M., De Angelis, R., Iezzi, S., Iacobini, C.,
Floridi, A., and Passananti, C. (2000). Identification of a novel partner of RNA
polymerase II subunit 11, Che-1, which interacts with and affects the growth
suppression function of Rb. FASEB J. 14, 904–912.
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., and Prives, C. (2001). A subset of
tumor-derivedmutant form of p53 down-regulate p63 and p73 through a direct
interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874–1887.
Gonzalez, S., Prives, C., and Cordon-Cardo, C. (2003). P73alpha regulation by
Chk1 in response to DNA damage. Mol. Cell. Biol. 23, 8161–8171.Gorgoulis, V.G., Vassiliou, L.-V.F., Karakaidos, P., Zacharatos, P., Kotsinas,
A., Liloglou, T., Venere, M., DiTullio, R.A., Jr., Kastrinakis, N.G., Levy, B.,
et al. (2005). Activation of the DNA damage checkpoint and genomic instability
in human precancerous lesions. Nature 434, 907–913.
Guo, Q., and Xie, J. (2004). AATF inhibits aberrant production of amyloid beta
peptide 1-42 by interacting directly with Par-4. J. Biol. Chem. 279, 4596–4603.
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid
degradation of p53. Nature 387, 296–299.
Irwin, M., Marin, M.C., Phillips, A.C., Seelan, R.S., Smith, D.I., Liu, W., Flores,
E.R., Tsai, K.Y., Jacks, T., Vousden, K.H., et al. (2000). Role for the p53
homologue p73 in E2F1-induced apoptosis. Nature 407, 646–648.
Li, W., Kim, S.-M., Lee, J., and Dunphy, W.G. (2004). Absence of BLM leads to
accumulation of chromosomal DNA breaks during both unperturbed and
disrupted S phases. J. Cell Biol. 165, 801–812.
Li, Y., and Prives, C. (2007). Are interactions with p63 and p73 involved in
mutant p53 gain of oncogenic function? Oncogene 26, 2220–2225.
Lin, W.-C., Lin, F.-T., and Nevins, J.R. (2001). Selective induction of E2F1 in
response to DNA damage, mediated by ATM-dependent phosphorylation.
Genes Dev. 15, 1833–1844.
Lindfors, K., Halttunen, T., Huotari, P., Nupponen, N., Vihinen, M., Visakorpi,
T., Maki, M., and Kainulainen, H. (2000). Identification of novel transcription
factor-like gene from human intestinal cells. Biochem. Biophys. Res. Commun.
276, 660–666.
Lissy, N.A., Davis, P.K., Irvin, M., Kaelin, W.G., and Dowdy, S.F. (2000).
A common E2F1 and p73 pathway mediates cell death induced by TCR acti-
vation. Nature 407, 642–645.
Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W.X., Corazzari, M.,
Knight, R.A., Green, D.R., Thompson, C., and Voudsen, K.H. (2004). p73
induces apoptosis via PUMA transactivation and Baxmitochondrial transloca-
tion. J. Biol. Chem. 279, 8076–8083.
Murphy, K.L., and Rosen, J.M. (2000). Mutant p53 and genomic instability in
a transgenic mouse model of breast cancer. Oncogene 19, 1045–1051.
Murphy, K.L., Dennis, A.P., and Rosen, J.M. (2000). A ‘‘gain of function’’
mutant promotes both genomic instability and cell survival in a novel
p53-null mammary epithelial model. FASEB J. 14, 2291–2302.
Nishino, K., Inoue, E., Takada, S., Abe, T., Akita, M., Yoshimura, A., Tada, S.,
Kobayashi, M., Yamamoto, K., Seki, M., and Enomoto, T. (2008). A novel role
for Rad17 in homologous recombination. Genes Genet. Syst. 83, 427–431.
Page, G., Lodige, I., Kogel, D., and Scheidtmann, K.H. (1999). AATF, a novel
transcription factor that interacts with Dlk/ZIP kinase and interferes with
apoptosis. FEBS Lett. 462, 187–191.
Passananti, C., Floridi, A., and Fanciulli, M. (2007). Che-1/AATF, a multivalent
adaptor connecting transcriptional regulation, checkpoint control, and
apoptosis. Biochem. Cell Biol. 85, 477–483.
Pediconi, N., Ianari, A., Costanzo, A., Belloni, L.,Gallo, R., Cimino, L., Porcellini,
A., Screpanti, I., Balsano, C., Alesse, E., et al. (2003). Differential regulation of
E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol. 5,
552–558.
Pilch, D.R., Sedelnikova, O.A., Redon, C., Celeste, A., Nussenzweig, M., and
Bonner, W.M. (2003). Characteristics of g-H2AX foci at DNA double-strand
breaks sites. Biochem. Cell Biol. 81, 123–129.
Ramadan, S., Terrinoni, A., Catani, M.V., Sayan, A.E., Knight, R.A., Mueller, M.,
Krammer, P.H., Melino, G., and Candi, E. (2005). p73 induces apoptosis by
different mechanisms. Biochem. Biophys. Res. Commun. 331, 713–717.
Rao, V.A., Conti, C., Guirouilh-Barbat, J., Nakamura, A., Miao, Z.-H., Davies,
S.L., Sacca`, B., Hickson, I.D., Bensimon, A., and Pommier, Y. (2007). Endog-
enous g-H2AX-ATM-Chk2 checkpoint activation in Bloom’s syndrome heli-
case-deficient cells is related to DNA replication arrested forks. Mol. Cancer
Res. 5, 713–724.
Rassool, F.V., North, P.S., Mufti, G.J., and Hickson, I.D. (2003). Constitutive
DNA damage is linked to DNA replication abnormalities in Bloom’s syndrome
cells. Oncogene 22, 8749–8757.Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc. 133
Cancer Cell
Che-1 Regulates Mutant p53 ExpressionRogakou, E.P., Pilch, D.R., Orr, A.K., Ivanova, V.S., and Bonner, W.M. (1998).
DNA double stranded breaks induce histone H2AX phosphorylation on serine
139. J. Biol. Chem. 273, 5858–5868.
Selivanova, G., andWiman, K.G. (2007). Reactivation of mutant p53:molecular
mechanisms and therapeutic potential. Oncogene 26, 2243–2254.
Sigal, A., and Rotter, V. (2000). Oncogenic mutations of the p53 tumor
suppressor: The demons of the guardian of the genome. Cancer Res. 60,
6788–6793.
Song, H., Hollstein, M., and Xu, Y. (2007). p53 ‘‘gain of function’’ cancer
mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9,
573–580.
Soussi, T. (2000). p53 antibodies in the sera of patients with various types of
cancer: a review. Cancer Res. 60, 1777–1788.
Stiewe, T., and Putzer, B.M. (2000). Role of the p53-homologue p73 in E2F1-
induced apoptosis. Nat. Genet. 26, 464–469.
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L.,
Levine, A.J., Sacchi, A., Cesarei, G., Oren, M., et al. (2000). Physical and func-
tional interaction between p53 mutants and different isoforms of p73. J. Biol.
Chem. 275, 29503–29512.
Strano, S., Dell’Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., and
Blandino, G. (2007). Mutant p53: an oncogenic transcription factor. Oncogene
26, 2212–2219.134 Cancer Cell 18, 122–134, August 17, 2010 ª2010 Elsevier Inc.Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M.G., Monti, O., Baccarini, A.,
Del Sal, G., Levrero, M., Sacchi, A., Oren, M., and Blandino, G. (2002). Physical
interaction with human tumor derived p53 mutants inhibits p63 activities.
J. Biol. Chem. 277, 18817–18826.
Thomas, T., Voss, A.K., Petrou, P., and Gruss, P. (2000). The murine gene,
Traube, is essential for the growth of preimplantation embryos. Dev. Biol.
227, 324–342.
Urist, M., Tanaka, T., Poyurovsky, M.V., and Prives, C. (2004). p73 induction
after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes
Dev. 18, 3041–3054.
Vousden, K.H., and Lu, X. (2002). Live or let die: the cell’s response to p53. Nat.
Rev. Cancer 2, 594–604.
Wang, X., Zou, L., Lu, T., Bao, S., Hurov, K.E., Hittelman, W.N., Elledge, S.J.,
and Li, L. (2006). RAD17 phosphorylation is required for claspin recruitment
and Chk1 activation in response to replication stress. Mol. Cell 23, 331–341.
Wiznerowicz, M., and Trono, D. (2003). Conditional suppression of cellular
genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol.
77, 8957–8961.
Wu, L. (2007). Role of the BLM helicase in replication fork management. DNA
Repair (Amst.) 6, 936–944.
Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L., and Trono, D. (1997). Multiply
attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat.
Biotechnol. 15, 871–875.
